Cardiovascular Disease After Hodgkin Lymphoma Treatment | Zendy

Frederika A. van Nimwegen | Zendy; Michael Schaapveld | Zendy; Cècile P.M. Janus | Zendy; Augustinus D. G. Krol | Zendy; Eefke Petersen | Zendy; John Raemaekers | Zendy; Wouter E.M. Kok | Zendy; Berthe M.P. Aleman | Zendy; Flora E. van Leeuwen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiovascular Disease After Hodgkin Lymphoma Treatment

Author(s) -

Frederika A. van Nimwegen,

Michael Schaapveld,

Cècile P.M. Janus,

Augustinus D. G. Krol,

Eefke Petersen,

John Raemaekers,

Wouter E.M. Kok,

Berthe M.P. Aleman,

Flora E. van Leeuwen

Publication year - 2015

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2015.1180

Subject(s) - medicine , incidence (geometry) , population , relative risk , heart failure , cohort , cumulative incidence , absolute risk reduction , disease , common terminology criteria for adverse events , adverse effect , pediatrics , confidence interval , physics , environmental health , optics

Hodgkin lymphoma (HL) survivors are at increased risk of cardiovascular diseases. It is unclear, however, how long the increased risk persists and what the risk factors are for various cardiovascular diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research